Frontier Biotech Reports Positive Data from HIV Treatment Trial

Nanjing Frontier Biotechnologies announced its long-acting HIV-1 inhibitor met the primary endpoint in a Phase III trial, based on an analysis of the interim data. Albuvirtide, administered once-weekly with ritonavir-boosted lopinavir, showed non-inferiority to a WHO-approved three-drug regimen. In the 48-week trial, albuvitide was administered as a second-line treatment to adults infected with HIV-1. Based on the results, Frontier will seek accelerated China approval of the drug from the CFDA. More details.... Share this with colleagues: // //